/
PSA-PN
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.76B | $2.86B | $2.92B | $3.42B | $4.18B | $4.52B | $4.70B | $4.82B |
| Cost of revenue | $757.1M | $813.2M | $867.5M | $920.6M | $1.05B | $1.15B | $1.26B | $3.62B |
| Gross profit | $2.00B | $2.04B | $2.05B | $2.50B | $3.13B | $3.37B | $3.44B | $1.20B |
| Gross margin | 72.6% | 71.5% | 70.2% | 73.0% | 74.8% | 74.6% | 73.2% | 25.0% |
| R&D | $5.4M | $6.8M | $10.8M | $8.4M | $17.5M | $0 | $0 | $0 |
| Operating income | $1.41B | $1.47B | $1.41B | $1.71B | $2.17B | $2.32B | $2.20B | $2.25B |
| EBITDA | $2.23B | $2.08B | $1.97B | $2.78B | $5.41B | $3.34B | $3.51B | $3.25B |
| Net income | $1.71B | $1.52B | $1.36B | $1.95B | $4.35B | $2.15B | $2.07B | $1.78B |
| Net margin | 62.0% | 53.3% | 46.6% | 57.2% | 104.0% | 47.6% | 44.1% | 37.0% |
| EPS (diluted) | 9.82 | 7.29 | 6.29 | 9.87 | 23.50 | 11.06 | 10.64 | 9.01 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5.1B | $10.11 | $9.40–$10.97 | 1 |
| 2027 | $5.5B | $9.90 | $9.21–$10.75 | 1 |
| 2028 | $5.7B | $10.52 | $9.78–$11.42 | 1 |
| 2029 | $6.3B | $10.63 | $9.89–$11.55 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$482.20
Price
$320.55
Implied upside
+50%
Peer comparison
Held by traders on TradeandTell
No one on the platform currently holds PSA-PN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PSA-PN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PSA-PN yet.